We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Regeneron launches five-year $500m biotech fund
1 HOUR AGO
Biopharma giant commits $100m annually to Regeneron Ventures as it seeks to ‘fuel promising biotech innovation.’
Yesterday, as we revealed 2023 was another tough year for longevity investment, biotech heavyweight Regeneron quietly announced the formation of Regeneron Ventures, a new $500 million venture capital fund. As the fund’s exclusive limited partner, Regeneron has pledged $100 million annually over the next five years to invest in promising life sciences companies.
While the new fund’s investment mandate is broadly health focused, Regeneron Ventures says its interest is “skewed towards biotechnology, devices, tools, and enabling technologies.” The fund says that investment decisions will be guided by the quality of the science, people, and data, prioritizing “breakthrough innovation” despite the inherent risks and uncertainties. All of which should resonate well with founders in the longevity sector, offering a potential new source of funding for biotech startups targeting aging and age-related diseases.
htTps://longevity.technology/news/regeneron-launches-five-year-500m-biotech-fund/amp/
SIRT6 is an enzyme that plays an essential role in human health and contributes to epigenetic regulation of gene expression, mitochondrial health, and DNA repair. A review of literature suggests that SIRT6 could potentially help address diseases of aging, neurodegeneration, diabetes and obesity, in addition to depression. Arrivo is exploring the potential of SP-624 in multiple therapeutic areas beyond depression.
Arrivo Bio Initiates Large Phase 2b Clinical Trial in Major Depressive Disorder with Novel SIRT6 Activator
Epigenetic mechanism of action offers a promising new approach to tackling MDD
April 16, 2024 08:00 AM Eastern Daylight Time
MORRISVILLE, N.C.--(BUSINESS WIRE)-
-Arrivo Bio announced today a significant step forward in the fight against major depressive disorder (MDD) with the dosing of the first patient in the SP-624-202 clinical trial.
htTps://www.businesswire.com/news/home/20240416487796/en/Arrivo-Bio-Initiates-Large-Phase-2b-Clinical-Trial-in-Major-Depressive-Disorder-with-Novel-SIRT6-Activator
THIS will get a few more longs in very tempted to add another lot here as want to build a nice lot for years to come
Lovely stuff MONEY! I think there’s maybe less than 25% free float. Saying that a lot of this is with people like us who will be here for the huge returns. All going to get very interesting very soon
Key highlights of the Founders Longevity Forum:
Exclusive event – The Founders Longevity Forum will host a minimum of 120 approved guests, including high-caliber investors, family offices, longevity founders and VIPs.
Comprehensive program – guests will enjoy a half-day of content, a welcome reception, a full-day program and automatic registration for London Tech Week.
Global reach – following the London event, the Founders Longevity Forum will travel to Abu Dhabi and San Francisco.
Longevity takes center stage – The Longevity Village at London Tech Week will elevate this dynamic industry, showcasing the companies applying new technologies to extend human healthspan.
htTtps://longevity.technology/news/founders-forum-and-longevity-technology-join-forces-to-accelerate-longevity-investment/
10th - 11th June 2024 - Organised by Longeity Technology who hold 3%. Gla ;-)
New international event program launches to bring longevity entrepreneurs and investors together.
Founders Forum and Longevity.Technology today announced the launch of the Founders Longevity Forum, a premier event series designed to educate and connect investors with the vast potential within the longevity market.
The inaugural Founders Longevity Forum will take place at Olympia London during the renowned London Tech Week, focusing on a sector that is projected to exceed $600 billion by 2025. This partnership aims to foster meaningful connections between startups, venture capitalists (VCs), corporate venture capitalists (CVCs), family offices and CEOs leading the charge in longevity.
Brent Hoberman, Co-Founder and Executive Chair of Founders Forum Group, said: “Longevity is becoming a mega trend as science makes increased healthspans more realistic, converging with a wider shift towards preventative healthcare.
“We’ve noticed a need to connect top scientists and innovative startups with funds to help them turn their dreams into reality. By bringing together the best and brightest minds working on longevity today, we can galvanize progress in this area and transform the demographic landscape.”
Taking place on New international event program launches to bring longevity entrepreneurs and investors together.4, the Founders Longevity Forum will address the investment opportunities across the longevity space, from established longevity business models such as diagnostics, longevity clinics and supplements, through to cutting-edge longevity biotech companies poised to revolutionize the biotech industry and transform society.
The event will also benefit from an advisory panel that has decades of longevity and geroscience expertise between them; the panel includes Eric Verdin, Andrea Maier, Jim Mellon and Aubrey de Grey, with further members to be announced.
“Multiple longevity events are happening and they’re all great, but few are specifically focused on bringing more investors into this rapidly accelerating field,” said Phil Newman, Founder and CEO, Longevity.Technology.
“We plan to stage events in London, Abu Dhabi and San Francisco initially to accelerate longevity investment globally, and catalyze a wave of innovation and collaboration that will redefine the future of human health.”
“We’re keen to educate investors on the vast opportunities in longevity whilst fostering meaningful connections for startups and scaleups in this niche,” said Carolyn Dawson, CEO, Founders Forum Group.
“Helping create these connections is central to our mission at Founders Forum Group as we seek to empower entrepreneurs at every stage of their journeys; with Longevity.Technology as our partner, we can forge formative alliances that propel longevity innovation.”
Major Shareholders
ERIC LEIRE 124,000,000 35.5%
PREMIER MITON 32,000,000 9.2%
ARIAN BEESTON 17,475,000 5.0%
JONATHAN MARK SWANN 16,874,000 4.8%
SAMANTHA BAUER 14,500,000 4.1%
LONGEVITY TECH FUND 10,499,998 3.0%
SARAH BEESTON 10,000,000 2.9%
Very impressive, this is going to bounce big very soon. Gl :-)
Thats 400k! Strong show of support!
MY SYSTEM reporting wrong he increased
MARM swan reduced great that it was pushed up for the sells
Good to see Mr Swann increase his holding! Orders being filled in the background, are premier Miton still buying but now from open market?
Good to see Swann increase his position from 3 to 5%.
Strong show of confidence that!
Eric's £50k share subscription declared along with another 1.8% for Jonathan Swan who declared his 3% back in March. The smart Money is accumulating. Gla :-)
Good to see the bulk buys still going through and stock being teased off weak hands.
Q2 and Q3 look set to be bumper!
Only the beginning!
Or que up to have some vax shots of that special brew SIRT6!
Hopefully the insiders who bought the subscription will also be buying open market with the new tax year and we’ll see a serious move now!
Great to see strong buying yet again. More shares going into serious investors hands. Free float shrinking as the days pass! Rerate
Great churn into sticky hands no doubt!
It's going to big...On and UP!!! Gla :-)
Good luck all
Let’s get things moving now :)
Cheers Porter, an excellent and informative interview and very encouraging on prospects and potential going forward. Exciting times ahead. Gl :-)